Natural Killer Cell

The FDA granted orphan drug designation to DF1001 for treatment of esophageal cancer.

Most patients who received one of two investigational natural killer cell therapy regimens for relapsed or refractory B-cell lymphoma achieved complete response, according to topline data released by the agents’ manufacturer.

A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial.

Pawel Kalinski, MD, PhD, has been promoted to Jacobs family endowed chair of immunology at Roswell Park Comprehensive Cancer Center.

The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with relapsed or refractory B-cell malignancies, according to the agent’s manufacturer.

The FDA granted orphan drug designation to CYNK-001 for the treatment of malignant gliomas, according to the agent’s manufacturer.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

Combining natural killer cells with high-dose chemotherapy and autologous stem cell transplant did not increase toxicity among patients with B-cell non-Hodgkin lymphoma, according to results presented at TCT Meetings Digital Experience.

Ryan Cassaday, MD, associate professor of hematology at University of Washington, discussed new platforms for cellular immunotherapy and the Devillier presentation of natural killer (NK) cells in a therapeutic setting presented at the ASH Annual Meeting and Exposition.

The FDA granted orphan drug designation to CellProtect, a modified natural killer cell therapy for the treatment of patients with multiple myeloma, according to the agent’s manufacturer.